Status and Problems of Adverse Event Reporting Systems in Korean Hospitals

被引:7
作者
Kim, Jeongeun [1 ,2 ]
Kim, Sukwha [3 ]
Jung, Yoenyi [4 ]
Kim, Eun-Kyung [5 ]
机构
[1] Seoul Natl Univ, Coll Nursing, 28 Yeongeon Dong, Seoul 110799, South Korea
[2] Seoul Natl Univ, Res Inst Nursing Sci, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Samsung Med Ctr, Dept Customer Satisfact, Seoul, South Korea
[5] Mokpo Natl Univ, Dept Nursing, Muan, South Korea
关键词
Patient Safety; Adverse Event; Reporting System;
D O I
10.4258/hir.2010.16.3.166
中图分类号
R-058 [];
学科分类号
摘要
Objectives: This study identifies the current status and problems of adverse event reporting system in Korean hospitals. The data obtained from this study will be used to raise international awareness and enable collaborative researches on patient safety. Methods: We distributed the questionnaire developed by the Agency for Healthcare Research and Quality (AHRQ), USA to the 265 risk managers of hospitals by e-mail. Seventy-two percent of the risk managers responded to the inquiry. Results: Eighty-five percent of the hospitals responded that they collect information regarding the event where harm has occurred or might have occurred to a patient. Seventy-five percent of the hospitals did not allow individuals to report occurrences without identifying themselves. Only 54% of the hospitals had an organized patient safety program that manages or coordinates all of the hospital's patient safety activities. The most frequent reason why errors were not reported was the fear of individuals being involved in the investigation and potential disadvantage resulting from it. Eighty-five percent of the hospitals produced reports of their adverse event data, but 68% of the hospitals did not distribute occurrence reports within the hospital. Conclusions: Lack of standardized reporting system, available information, procedures for protecting the reporting individuals, and mindlessness/indifference of the hospital employees are identified as the major problems. Therefore, it is crucial to address these problems to develop appropriate solutions, enable proactive involvement from the healthcare community, and change the overall patient safety culture, specifically protecting privacy, to increase the quality of service in the healthcare industry.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 50 条
[32]   Simulation Based Adverse Event Reporting System: Development and Feasibility [J].
McKay, Mary ;
Sanko, Jill S. .
CLINICAL SIMULATION IN NURSING, 2014, 10 (05) :E261-E269
[33]   Evaluation of a prospective adverse event reporting system in interventional radiology [J].
Mulvihill, S. B. ;
Healy, G. M. ;
O'Rourke, C. ;
Cantwell, C. P. .
CLINICAL RADIOLOGY, 2021, 76 (09) :659-664
[34]   Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system [J].
Huang, Qing ;
Wu, Yuanbin ;
Li, Huimin .
EXPERT OPINION ON DRUG SAFETY, 2025, 24 (02) :221-231
[35]   DIFFICULTIES AND STRATEGIES OF PATIENT SAFETY CENTERS IN REPORTING ADVERSE EVENTS IN HOSPITALS [J].
Andrade, Monica Maria de Melo ;
Viana, Adane Domingues ;
Queluci, Gisella de Carvalho ;
Couto, Jackeline Franco ;
Tonini, Teresa .
REVISTA DE PESQUISA-CUIDADO E FUNDAMENTAL ONLINE, 2025, 17
[36]   Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS) [J].
Xiong, Xiaomei ;
Zhang, Xiuwen ;
Li, Xiaoxia ;
Huang, Taomin .
EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) :1447-1452
[37]   Adverse Event Profile of Tigecycline: Data Mining of the Public Version of the US Food and Drug Administration Adverse Event Reporting System [J].
Kadoyama, Kaori ;
Sakaeda, Toshiyuki ;
Tamon, Akiko ;
Okuno, Yasushi .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (06) :967-970
[38]   Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System [J].
Mai, Haiyan ;
Zhang, Zhenpo ;
Liang, Yankun ;
Zheng, Jingping ;
Su, Ling .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2025, 16
[39]   Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system [J].
Song, Qi ;
Gao, Siyuan ;
Tan, Yaqian .
JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01)
[40]   Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system [J].
Cao, Bing ;
Gu, Shanshan ;
Shen, Zhisen ;
Zhang, Yuna ;
Shen, Yiming ;
Chen, Hang .
EXPERT OPINION ON DRUG SAFETY, 2023, :297-303